Amatuer , I believe that you underestimate our combo...
In USA only it is estimate that in 2020 will be over 260,000 patients with MDR2 , it means about 180,000 will be CCR5 positive.
And about 25,000 MDR3 patients , so about 17,000 CCR5 positive.
Right now for MDR2 we have only Maraviroc
and for MDR3 Maraviroc and IV Ibalizumab.
-Maraviroc efficacy is 45% after 48 weeks
-Ibalizumab efficacy is 43% after 24 weeks
-Leronlimab efficacy is 81% with 350 mg after 24 weeks , most probably will be higher with 525 mg .
As a physician I will put all mine MDR2 , CCR5 positive patients on Leronlimab , so they will not progress to MDR3.
Patients with MDR3 are usually very sick already ..
Another thing Dr NP said recently , that as soon as we be approved in USA they be asking for approval in Europe , and Europe is twice as big.
So some might be surprise with our combo.
When mono will be approved some patients I believe will go only on mono , but until than we just need to educate our physicians...
And as always IMO.
Market Data 
Markets 
AI
